Can I Participate?
You may be eligible to participate in this study if you:
Are 18 years of age or older
Have a confirmed
diagnosis of systemic lupus erythematosus (SLE) and/or lupus nephritis (LN)
“Refractory” means that your systemic lupus erythematosus (SLE) and/or lupus nephritis (LN) does not respond to standard therapies or medications.
Other eligibility criteria apply and will be evaluated by a study doctor.
You have been informed by your doctor that your systemic lupus erythematosus (SLE) and/or lupus nephritis (LN) is refractory
What is the Purpose of Artiva’s AlloNK® Study?
The main purpose of this study is to learn if AlloNK® (AB-101), an investigational treatment, is safe for people with systemic lupus erythematosus (SLE) and/or lupus nephritis (LN) and if AlloNK® can help improve their condition.
The study will also look at how well the treatment is tolerated and how the body responds to AlloNK®.
What is AlloNK® (AB-101)?
AlloNK® (AB-101) is an investigational treatment being studied to see if it can reduce B-cells that cause systemic lupus erythematosus (SLE) and/or lupus nephritis (LN). AlloNK® works by boosting your immune system using NK cells* from healthy donors, along with other treatments.
NK cells help protect your body from harmful invaders. When paired with another type of treatment called mAb therapy (example: rituximab), they may target the faulty B-cells that cause the symptoms of systemic lupus erythematosus (SLE) and/or lupus nephritis (LN). AlloNK® can be given outside of hospitals, in places like clinics or doctor’s offices, making it easier for you to potentially participate.
*Natural killer (NK) cells: A type of immune cell that helps protect the body from infections and cancer. NK cells attack infected or abnormal cells but also avoid harming normal cells. NK cells are special because they can be used to treat many patients without needing gene editing or other genetic changes.
*Natural killer (NK) cells: A type of immune cell that helps protect the body from infections and cancer. NK cells attack infected or abnormal cells but also avoid harming normal cells. NK cells are special because they can be used to treat many patients without needing gene editing or other genetic changes.
Why Should I Join
Artiva’s AlloNK® Study?
By enrolling in this study, you may receive:
Access to expert physicians with experience managing systemic lupus erythematosus (SLE) and/or lupus nephritis (LN).
Your participation supports the advancement of treatments for individuals with systemic lupus erythematosus (SLE) and/or lupus nephritis (LN).
Frequently Asked Questions
AlloNK® is designed to boost the immune system by using NK cells that are donated by health volunteers. It’s meant to work with other treatments and can be given outside the hospital, in places like clinics or doctor’s offices.
The study will take around 24 months. You will have 26 office visits over the 2 years.
Clinical research depends on volunteers like you to participate to help improve treatments and advance medical knowledge. Participants play a key role in finding safe and effective therapies. Participating is a personal choice. You may decide not to participate, or you may leave the study at any time.
Your participation in this clinical study helps us learn more about systemic lupus erythematosus (SLE) and/or lupus nephritis (LN) and, hopefully, find a new and accessible treatment.
If you participate in this clinical study, you will get:
-
Access to trying an investigative treatment that
may work for you -
Extra tests and monitoring from study doctors
-
While we try to lower risks as much as possible, some side effects may occur. But the clinical study team will watch you closely, adding another layer of care.
The Sponsor will cover all costs for the AlloNK study treatment, as well as any study-related visits, tests, hospitalizations, and procedures done specifically for the study. The Sponsor will cover the costs of travel, hotels, and meals associated with participation in the study.
If you are an adult with systemic lupus erythematosus (SLE) and/or lupus nephritis (LN) and other treatments have not worked well, this could be the right study for you. Complete the form below to learn more about AlloNK® for SLE and/or LN.
I am interested in the clinical study!
Please complete the form and we will contact you with more information
